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Supplementary Methods

Data
GWAS Catalog
We use the NHGRI GWAS catalog (Hindorff et al. 2009 , http://www.genome.gov/gwastudies downloaded on August 10, 2011) to obtain a list of GWAS associations. The version of the catalog we use contains 5922 entries. Each entry associates a SNP with a phenotype in a study. Most studies report several associated SNPs and each of them has a separate entry. A SNP associated with two phenotypes in the same study results in two entries entries. The GWAS catalog provides additional information for each entry. We use information about the genotyping technology used (Affymetrix, Illumina or Perlegen), whether the SNP was directly genotyped or imputed, the statistical support for the association (P-value), the population(s) in which the study was performed and the presence or not of a replication cohort. We map each entry in the GWAS catalog to dbSNP 131, which results in a total of 5694 associations on the autosomes and on chromosome X. We exclude the single association on chromosome Y from our analysis. The 5694 associations represent a total of 4724 distinct SNPs, 470 phenotypes and 810 studies. 416 SNPs are associated in more than one study.
Linkage Disequilibrium
We use HapMap version 2 (The International HapMap Consortium 2007) and version 3 (The International HapMap Consortium 2010) in order to obtain Linkage Disequilibrium information between SNPs. HapMap 2 provides a higher SNP density, whereas HapMap 3 provides information for more populations. The HapMap 2 data we use includes 2,776,528 SNPs in the CEPH (Utah residents with ancestry from northern and western Europe, abbreviation: CEU) population, 2,554,939 SNPs in the Han Chinese in Beijing, China (abbreviation: CHB) population, 3,114,362 SNPs in the Yoruba in Ibadan, Nigeria (abbreviation: YRI) population, and 2,509,881 SNPs in the Japanese in Tokyo, Japan (abbreviation: JPT) population. We create an intersection set that includes all 2,135,736 SNPs that are assessed in all four HapMap 2 populations. We use HapMap 2 and HapMap 3 data in order to create a list of pairs of SNP for which there is some evidence of LD (r 2 ! 0.1) in any HapMap 2 or HapMap 3 population.
Functional annotations
We use RegulomeDB in order to annotate SNPs with regulatory information. RegulomeDB integrates various types of assays, including DNaseI-seq peaks and ChIP-seq peaks, both generated by the ENCODE consortium, DNaseI footprints, conserved motifs, eQTLs curated from several studies in multiple tissues, and validated functional loci. For each SNP RegulomeDB provides a list of datasets in which there is evidence of function in a region overlapping the SNP, as well as a score indicating the confidence that the SNP is functional based on all the available evidence for the locus. The RegulomeDB paper describes the database and scoring metric in more details (Boyle et al. 2012 ).
We run RegulomeDB on every SNP in dbSNP 132. There is some evidence of function for a total of 13,453,666 SNPs (50.7%). In this study, we use a slightly modified format of the RegulomeDB scores in order to integrate linkage disequilibrium and eQTL information. A RegulomeDB score of 1a through 1f indicates that a SNP is an eQTL, with the letter indicating how much other functional information supports there is for the SNP. Each letter maps to another score (2a through 5), with the only difference being that the higher scores denote SNPs that are not eQTLs. We map scores between 1a and 1f back to the corresponding scores between 2a and 5, and handle eQTLs separately. We also create two additional scores, 5a for SNPs overlapping ChIP-seq peaks only, and 5b for SNPs overlapping DNaseI-seq peaks only, whereas RegulomeDB uses a score of 5 for both. Supplementary Table 1 provides an overview of the modified scoring scheme.
Transcribed regions
We use GENCODE v7 (Harrow et al. 2012 ) to identify SNPs that overlap transcribed regions. We intersect the GENCODE v7 Genes basic set track from the UCSC browser with all SNPs in dbSNP 132 and determine whether the SNP lies in an exon. If the SNP is in an exon, we use the coding region start and end information of the browser table in order to determine whether the SNP is in a coding region or is in a non-coding part of an exon. We consider introns in a similar way than intergenic regions since regulatory elements can be found in both. This leads to a transcriptional annotation for each SNP.
Discussion of the integration of linkage disequilibrium information
The use of linkage disequilibrium to identify functional SNPs is based on the assumption that the linkage disequilibrium structure used in this analysis is the same than in the population in which the association study was performed. This assumption is necessary in order to consider that a functional SNP in strong linkage disequilibrium with a lead SNP is associated with the phenotype. If the two SNPs are not correlated in the actual study population, then there is no evidence that the functional SNP has an effect on the phenotype. Linkage disequilibrium patterns differ significantly between populations, and it is therefore challenging to obtain linkage disequilibrium information that closely matches the population in which the GWAS was performed. We choose to use a conservative approach in which we consider two SNPs to be in strong linkage disequilibrium only if they are in strong linkage disequilibrium (r 2 ! 0.8) in all four HapMap 2 populations. These populations are of European, African, Japanese and Chinese origin, and thus encompass a large part of the variation between populations, and in particular represent populations that diverged early on in recent human evolution. Linkage disequilibrium patterns that are conserved across all four populations are likely to be conserved in the populations studied in GWAS as well, and this approach should thus reduce the number of false positives amongst the functional SNPs we identify. This clearly comes at the cost of sensitivity: when considering SNPs in strong LD with the lead SNP in all populations, 33% of the lead SNPs are annotated but have no SNP in LD with them. We separately repeat our analysis by considering functional SNPs that are in strong LD in the CEU HapMap population with a lead SNP associated with a phenotype in a population of European descent. This increases the number of SNPs assessed for functional evidence. The fraction of lead SNPs that are mapped to a functional SNP also increases: 80% of the lead SNP are found to be in strong LD with a SNP overlapping a region identified to be functional in at least one ENCODE assay. Recent analysis of the genetic structure of the European population do however show significant differences between different sub-populations, and it is therefore important to keep in mind that further analysis is needed, as the correlation between a lead SNP and an functional SNP in the HapMap CEU population might be weaker the population in which the original association was performed.
Randomizations
We create null sets in which each lead SNP is matched to a random SNP that shares the same properties. We then repeat the annotation steps on each null set, and obtain an empirical distribution of the fraction of functional SNPs expected for matched SNPs, and of the score distribution amongst matched SNPs.
Filtering
In order to obtain null sets that are similar to the set of associated SNPs, we only consider SNPs that were assessed in all HapMap 2 populations, for which the minor allele frequency is known in dbSNP, and that we can map to a genotyping platform. We use the GWAS catalog to determine whether an associated SNP was found using an Affymetrix or an Illumina array, and then determine whether the SNP is the corresponding list of SNPs we have previously computed. If the SNP is not in the list, or if the platform is not Affymetrix or Illumina, then the lead SNP is filtered out. An exception is the case where the SNP was found using imputation, in which case the SNP is kept in the set as long as it is in HapMap 2. A total of 1160 lead SNPs are filtered out at this stage. We then search for pairs of lead SNPs that show some evidence of linkage disequilibrium between them (r 2 ! 0.1 in any HapMap 2 or HapMap 3 population). For each such pair we keep only the lead SNP with the stronger association (more significant P-value reported in the GWAS catalog), and repeat this process until no pair of SNPs in linkage disequilibrium with each other is left in the filtered set. A total of 1200 lead SNPs are filtered out due to LD, leaving us with a set of 2364 SNPs. We repeat the annotation steps on this new set, and perform all enrichment comparisons using this set and its subset of European association, which is obtained in a similar way than for the set of all lead SNPs.
Matched null sets
We compute several matched null sets that model the properties of the associated SNPs increasingly closely. We group SNPs into bins based on their minor allele frequency, with each bin representing a 5% minor allele frequency interval. For all null sets, a lead SNP is always matched to a random SNP in the same minor allele frequency bin. We also ensure that SNPs in each null set are not in linkage disequilibrium with each other, using the same criterion than for the lead SNPs. The null-dbSNP set is obtained by matching each lead SNP to a SNP in dbSNP 132. The null-HapMap2 set is obtained in a similar way, except that the matched SNPs must be amongst the SNPs assessed in all HapMap 2 populations. The null-Array set is obtained by matching a lead SNP with a SNP that appears on the same platform (Illumina or Affymetrix) than the lead SNP, or a SNP that is in HapMap 2 if the SNP has been imputed. If the original study includes both Affymetrix and Illumina platform, and the lead SNP is present on both, then the SNP is matched to a random SNP from either platform. The null-Array-Function set uses the same criteria than the null-Array set, but in addition also requires that the matched lead SNP is in the same functional category (as predicted using UCSC genes, see above) than the lead SNP. Finally, the null-Array-Function-Distance is obtained by also requiring that the matched SNP is at a similar distance to the nearest transcription start site (with respect to UCSC genes) than the lead SNP if the lead SNP is located in an intergenic region or an intron. We group SNPs into bins according to the logarithm of their distance to the nearest transcription start site, and each bin represents a log 10 (distance) interval of 0.1. All SNPs with a log 10 (distance) under 3.5 are grouped into one bin, and all SNPs with a log 10 (distance) above 13 are grouped into one bin. While we use all these random null sets in Figure 3B and 3C, enrichments presented in Table 3 and Figure 3A are only computed using the most stringent null-Array-Function-Distance sets.
Discussion of the randomization approach
We use a conservative approach in order to estimate enrichment. We do so in two steps, by first filtering lead SNPs and then generating random null sets that closely match the properties of the lead SNPs. In the filtering step, we ensure that the lead SNPs that we use when computing enrichment are independent. If two lead SNPs were in strong linkage disequilibrium, then the set of SNPs in LD would likely overlap, and a functional region in LD with both SNPs would be double counted. This is a fairly likely situation given that there are large regions of perfect linkage disequilibrium, and different chips use different tag SNPs to genotype the same region. If a phenotype is assessed on two different platforms, then two different SNPs could be reported as significant even though they are both in the same associated region. Accurately replicating the fine linkage disequilibrium structure between lead SNPs when building random null sets would be extremely challenging, and we therefore decide to consider only SNPs that are not in LD with each other in order to estimate enrichment. Second, as our method for identifying associated functional SNPs relies on linkage disequilibrium information from HapMap, we do need to ensure that the fraction of SNPs that are assessed in HapMap does not differ substantially between the actual lead SNP set and the random sets. If we had allowed a lead SNP to be matched to any SNP in dbSNP, then LD information would only be available for a small subset of the random null sets, which would artificially decrease the number of functional SNPs identified in those random sets. In order to avoid any subtle difference that could bias our enrichment estimation, we limit the set of lead SNPs to SNPs that have been assessed in all four HapMap 2 populations, and similarly limit the set of random SNPs. While this substantially decreases the set of lead SNPs that are used to compute enrichment estimates, the fraction of lead SNPs overlapping functional regions in this smaller set (Supplementary Tables  4, 5 ) is comparable to using all reported associations (Supplementary Tables 2, 3) . We then compute a random set that matches the properties of the lead SNPs. A lead SNP is matched to a SNP with similar minor allele frequency, since minor allele frequency can affect the strength of the statistical association between a SNP and a phenotype. We then map each lead SNP to another SNP on the same genotyping array. This corrects for biases that may result from the choice of SNPs put on the genotyping array. We also map a lead SNP to a SNP that has the same function (with respect to UCSC genes), such that the fraction of coding SNPs, for example, is the same in the random sets than amongst lead SNPs. Finally, we also ensure that each lead SNP is mapped to a random SNP that is at a similar distance to nearest transcription start site. This avoids the situation in which an association that is close to a gene, and thus more likely to overlap with some functional data is matched by a SNP in a so-called gene desert in a null set. We still obtain significant enrichment for functional regions even when taking all these factors into account, and when comparing the most stringent random set to all lead SNPs. While using such a conservative approach and still reaching significance is strong evidence that there is enrichment for functional elements in regions associated with disease and other phenotypes, one can argue that matching the properties of lead SNPs that closely actually amounts to overcorrecting. For example, while there appears to be a bias for associated SNPs to be closer to known genes than random SNPs on the same genotyping chip, this is actually a biologically interesting property of disease associations. By requiring the matched null sets to also lay more close to known genes, we increase the probability that those random SNPs are in regulatory regions, or in strong LD with a regulatory region. It is likely that the functional SNPs identified when using random null sets, and in particular those supported by multiple types of functional data, also affect some phenotype in some way, but that this association has yet to be discovered in a GWAS.
INTRODUCTION
High throughput functional information has also been used to identify a large number of enhancers in the 9p21 region, and determine that two SNPs associated with coronary artery disease overlap with an enhancer and disrupt a STAT1 binding site (Harismendy et al. 2011 ).
We discuss several specific functional SNPs, and in particular provide evidence indicating that rs1333047, a SNP in perfect linkage disequilibrium with coronary artery disease associated SNP rs1333049 in the CEU population only, is likely a functional SNP. This result can explain why the association between rs1333049 and coronary artery disease has not been replicated in populations of African descent.
RESULTS
The 9p21 gene desert is a region that contains multiple SNPs that are strongly associated with coronary artery disease. We consider the functional information available from ENCODE in order to generate candidate functional SNPs in this region. The association between rs1333049 and coronary artery disease has been replicated in multiple studies in populations of European descent (WTCCC 2007 , Samani et al. 2007 , Broadbent et al. 2008 , Wild et al. 2011 as well as in populations of Japanese and Korean descent (Hiura et al. 2008 , Hinohara et al. 2008 ). In the HapMap 2 CEU population, this SNP is part of a haplotype block that includes rs10757278 and rs1333047, both of which are in perfect LD with rs1333049. rs10757278 has also been itself associated with coronary artery disease in multiple populations of European descent (Helgadottir et al. 2007 , Broadbent et al. 2008 and in the Chinese Han population (Ding et al. 2009 ). Figure  6 (main manuscript) provides an overview of this region. There is no evidence supporting a functional role for rs1333049. However, both rs10757278 and rs1333047 overlap a DNase hypersensitivity peak as well as ChIP-seq peaks for STAT1 and STAT3 in HeLA-S3 cells, and are therefore functional SNPs. Furthermore, rs10757278 lies in a STAT1 binding site, and rs1333047 lies in a binding site and a DNaseI footprint for Interferon-stimulated gene factor 3 (ISGF3). The motif is a good match when extending the less specific part of the motif (positions 8-9) located between the two very specific regions (positions 2-7 and 10-13) by a base pair. This is similar to cases of variable spacer length previously observed for transcription factor binding motifs (Badis et al. 2009 ). While the functional role of rs10757278 has been previously reported (Harismendy et al. 2011) , evidence of the functional role of rs1333047 is novel. Interestingly, while only 27 base pairs separate the two SNPs, they are in perfect linkage disequilibrium in the CEU population only. The frequency of the 'A' allele at rs1333047 in the Yoruba in Ibadan, Nigeria (YRI) HapMap 2 population is only 0.8%, compared to 50.8% in the CEU population. This allele is part of the protective haplotype found in GWAS performed in populations of European descent. The 'A' allele is part of the motif for ISGF3 binding, whereas the 'T' allele is not.
The most recent meta-analysis in populations of European descent (Schunkert et al. 2011 ) identifies rs4977574 as the most strongly associated locus in 9p21. We find that this SNP overlaps DNase hypersensitivity peaks in two ENCODE cell lines (Hah and Lncap), a conserved motif for the Androgen Receptor (AR), and a ChIP-seq peak for AR in a data set from Wei et al. (Wei et al. 2010) . The RegulomeDB score for this SNP is 2c. In the YRI population, the minor allele frequency of this SNP is only 7.5%, and it is in strong LD with rs10757278 (r 2 = 0.803) and in weaker LD with rs1333049 (r 2 = 0.382). It is in strong LD with both in the CEU population (r 2 of respectively 0.874 and 0.885). Previously identified functional candidate rs1333045 (Jarinova et al. 2009 ) obtains a RegulomeDB score of 3a, as it overlaps a conserved motif (Hand1::Tcfe2a), a ChIP-seq peak for GATA3 in the T-47D ENCODE cell line, and a DNase peak in the Huvec ENCODE cell line. This SNP has a minor allele frequency of 45.8% in the YRI population, and is in weak LD with both rs10757278 (r 2 = 0.119) and rs1333049 (r 2 = 0.251). In the CEU population it is in strong LD with both (r 2 of respectively 0.808 and 0.815).
DISCUSSION
A new functional SNP in 9p21 could explain the lack of association in populations of African descent
We identify rs1333047 as a candidate functional SNP in the 9p21 region. This region is associated with coronary artery disease (McPherson et al. 2007 ) and several other diseases, and the risk of coronary artery disease for the 25% of individuals in populations of European descent that are homozygous for the risk allele is two times higher than for individuals homozygous for protective alleles (McPherson 2010) . This region is a gene desert, but the non-coding RNA ANRIL overlaps the SNPs associated with coronary artery disease (Broadbent et al. 2008) . A recent study in mice showed that the deletion of the region orthologous to 9p21 leads to changes in the expression of the orthologs of the two human genes closest to 9p21, cyclin-dependent kinase inhibitors genes CDKN2A and CDKN2B, and has effects on the phenotype (Visel et al. 2010) . SNPs associated with coronary artery disease affect the expression of ANRIL, and to a smaller extent CDKN2A and CDKN2B in human (Cunnington et al. 2010 . Given the perfect LD in this region, they are likely also homozygous respectively for the risk and protective alleles at rs1333047. They show that in cell lines homozygous for the protective allele, STAT1 knockdown leads to a 7-fold upregulation of the expression of ANRIL, a non-coding transcript located in the 9p21 region, whereas there is a much smaller effect in cell lines homozygous for the risk allele. This would, however, also be consistent with an effect caused by rs1333047 since STAT1 is part of the ISGF3 complex, and a knockdown of STAT1 would therefore also affect ISGF3. Furthermore, they use ChIP to identify that STAT1 binds at rs10757278 only in cell lines with the protective allele. Binding of STAT1 in this region does not imply the absence of ISGF3 binding, and given that STAT1 is part of of the ISGF3 complex, it is also possible that ISGF3 binding was detected rather than binding of the STAT1-STAT1 homodymer. Finally, Harismendy et al. show that treatment with Interferon-" leads to a change in expression of ANRIL in HeLA and HUVEC cell lines. As Interferon-" is only know to be involved in the Type-II-Interferon pathway, this cannot be explained by ISGF3 binding to the ISRE at rs1333047. This change is, however, in the opposite direction to the change expected from the observation in the STAT1 knockdown experiment, which indicates that there might be multiple binding sites at play in this region. The evidence is therefore compatible with a functional role for both rs1333047 and rs10757278.
While both functional SNPs are in perfect linkage disequilibrium in the HapMap 2 CEU population, as well as in the individuals studied by Harismendy et al., this is not the case in other populations. In particular, the protective allele at rs1333047 is rare (0.8%) in the HapMap 2 YRI population. Major differences in allele frequency and linkage disequilibrium structure between populations in the 9p21 region have been previously identified (Silander et al. 2009 ). Interestingly, multiple GWAS of coronary artery disease in populations of African descent failed to replicate the association at rs1333049 (Assimes et al. 2008 ) and rs10757278 (Kral et al. 2011 , Lettre et al. 2011 . While these studies did not replicate the most strongly associated SNPs in European populations, they did identify SNPs that are associated with coronary artery disease in populations of African descent. Two additional associatied SNPs, rs10757274 and rs2383206 were identified in the European (McPherson et al. 2007 ), South Korean but not replicated in African-American (McPherson et al. 2007 ). rs10757274 has been associated with heart failure in individuals of European descent, but the association was not significant in African American (Yamagishi et al. 2009 ). Therefore there is strong evidence that associations with coronary artery disease identified in population of European origin in 9p21 are not replicated in populations of African origin. If rs10757278 is the functional SNP that has the largest effect on the phenotype in this region, then the absence of replication can only be explained by an interaction between the effect at rs10757278 and some other region in which the populations of African descent differ from the populations of European descent. If, however, rs1333047 functionally affects the phenotype, then the lack of replication can be explained by the lack of linkage disequilibrium between rs1333047 and the genotyped SNPs. Therefore, the lack of replication of this finding in populations of African descent supports rs1333047 as a candidate functional SNP in this region. Furthermore, rs1333047 is the strongest association with coronary artery disease association identified in an African American population using a method that combines association and admixture information (Pasaniuc et al. 2011 ).
The linkage disequilibrium patterns also differ between the HapMap 2 CEU population and the two Asian populations (CHB and JPT). Linkage disequilibrium does, however, remain relatively high (r 2 of respectively 0.978 and 0.442 between rs1333047 and associated SNPs rs10757278 and rs1333049). A large scale, gene centric analysis (IBC 50K CAD Consortium 2011) showed that the effect size for the association between 9p21 SNP rs1333042 and coronary artery disease was larger in European than Asian (odds ratio of respectively 1.27 and 1.14). We analyze the linkage disequilibrium between rs1333047 and haplotypes identified in previous studies in the Han Chinese population (Ding et al. 2009 ), which includes rs2383206, rs1004638, rs17761446 and rs10757278. Only haplotype AATA includes the protective 'A' allele at rs1333047, and rs1333047 is in strong linkage disequilibrium (r 2 = 0.975) with rs1004638. The AATA haplotype is more frequent in controls (30.5%) than in cases (27.3%) . Similarly, we analyze the haploblock reported in an association study of the Korean population . Only two SNPs, rs2383206 and rs10757278 are also in HapMap 2. For these SNPs, only haplotype AA includes the protective 'A' allele at rs1333047, and this haplotype is protective in the Korean population, with a frequency of 52.1% in controls and 45.1% in cases. Therefore previous results in population of Asian ancestry are also compatible with a potential functional role of rs1333047.
The implications of this potential functional association are significant. A recent meta-analysis of 7 independent studies with a total of 9,487 cases and 30,171 controls (Wild et al. 2011 ) identifies rs1333049 as the strongest association with coronary artery disease (P-value 7.12#10 $58 , odds ratio 1.27). The original study that associates rs10757278 with coronary artery disease in the Icelandic population and three populations in the United States (Helgadottir et al. 2007) shows that the odds ratio for heterozygous carriers of the risk allele is 1.26, and the odds ratio for the homozygous carriers is 1.64, and that this association alone might explain up to 21% of the population attributable risk. This study did not specifically analyze rs1333047. Since all three SNPs are part of the same haplotype in the CEU population, and are perfectly correlated, the odds ratios and attributable risks would be similar for rs1333047. The differences in LD structure however mean that both rs10757278 and rs1333049 are poor proxies for rs1333047 in other populations. This has important implications in personalized medicine, as testing those SNPs would lead to incorrect risk predictions if rs1333047 is indeed the mutation that plays a functional role in the phenotype. Furthermore, a potential functional role for rs1333047 would mean that the Type-I-Interferon signaling pathway plays a role in the association at 9p21, in addition to the Type-II-Interferon pathway previously identified by Harismendy et al. Finally, it is important to note that in YRI the frequency of the protective allele is very low (0.8%), meaning that most individuals in populations of African descent might be at a higher risk for coronary artery disease if rs1333047 is the mutation that plays a functional role in the disease. Interestingly, given the low minor allele frequency at rs1333047 in the YRI population, even genotyping this locus would require a much larger population in order to reach statistical significance in this population. This example illustrates the power of combining the results of functional studies such as ENCODE with results from GWAS in multiple population, and in particular in considering populations in which replication of an association were unsuccessful together with linkage disequilibrium data. Further experimental validation of the binding of ISGF3 to this region, of the effect of rs1333047 on this binding site, and of the association between rs1333047 and coronary artery disease across populations are however necessary to definitely prove that rs1333047 is a functional SNP linked to coronary artery disease. Given the evidence supporting a functional role for multiple loci in tight linkage disequilibrium in 9p21, it appears likely that multiple SNPs in binding sites for transcription factors that are part of a broad range of pathways together play a role in the biological process underlying the association of this region with coronary artery disease.
